Ortho Regenerative Technologies Inc (CSE:ORTH) CEO Philippe Deschamps joined Proactive's Stephen Gunnion with details of a $500,000 grant from Axelys to advance the development of its second technology platform indication, ORTHO-M, for meniscus repair.
Deschamps telling Proactive that the grant, through its partnership with Polytechnique Montreal, consolidates the significant multi-indication potential of its drug/biologic PRP combination product for soft tissue repair.
Importantly, he said it will also serve to validate the multi-indications potential of the company's soft tissue repair platform.